• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

TriSalus, University of Texas to collaborate on solid tumor treatment study

April 8, 2021 By Sean Whooley

TriSalus-logoTriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors.

The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy, according to a news release.

Under the collaboration, the center and TriSalus will evaluate the administration of SD-101 intravascularly using the latter’s FDA-cleared, proprietary pressure-enabled drug delivery (PEDD) technology to treat liver and pancreatic solid tumors.

The initial study is slated to focus on liver metastases from uveal melanoma, which will be followed by studies on metastatic disease from pancreatic ductal adenocarcinoma and colorectal cancer. The collaboration is also developing programs for hepatocellular carcinoma and locally advanced pancreatic ductal adenocarcinoma, with TriSalus providing the funding and technology for the studies.

TriSalus’ PEDD delivers immuno-oncology therapeutics directly into the vasculature of solid tumors. The investigational SD-101 has already been evaluated in Phase 2 studies in advanced cutaneous melanoma and head and neck cancer. The planned studies under the collaboration are set to deliver SD-101 with PEDD, utilizing a technique not previously available through standard delivery approaches.

“We’re pleased to collaborate with MD Anderson in pursuit of our collective goal to improve outcomes for patients with tumors of the liver and pancreas. The goal of these studies is to augment the potential of existing therapies through novel drug delivery technology and to investigate the strategic modulation of immune microenvironments with investigational candidate SD-101,” TriSalus CMO Dr. Steven Katz said in the release. “Collaborations such as this are an integral part of our development strategy to evaluate treatments to help overcome the challenges inherent to solid tumors and enable a broader population of cancer patients to benefit from immunotherapy.”

“Tumors in the pancreas and liver are notoriously difficult to treat effectively, and these patients need new therapeutic options. Our collaboration with TriSalus provides a unique opportunity to evaluate immunotherapy in combination with a novel delivery approach,” added MD Anderson associate professor of melanoma medical oncology Dr. Sapna Patel. “We look forward to our work together to advance new treatments aimed at improving clinical outcomes and the lives of our patients.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology Tagged With: trisaluslifesciences, University of Texas MD Anderson Cancer Center

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS